New combo therapy shows promise in brain cancer trial
Disease control
Completed
This study tested whether adding the drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe and shows early signs of working in people with newly diagnosed glioblastoma, a fast-growing brain cancer. 33 participants received the combination. The main goals w…
Phase: PHASE1, PHASE2 • Sponsor: Cantex Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC